LONDON (ShareCast) - Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments.

The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrated a mean response with at least a 50% reduction in the rate of tumour growth in an accepted standard cancer model.

"With the science progressing on schedule, I am delighted to be able to report the successful completion of our non-small cell lung cancer pre-clinical efficacy studies," said group chief executive Dr Suzanne Dilly.

"These results allow us to plan our course through the regulatory pathways into a full clinical study."

The company said it believes the positive results confirm the promise shown by the earlier reported cellular assay results and it expects the formulation and preliminary pre-clinical toxicology results to be collated by the end of the year.

Valirx shares were up 4.81% to 0.41p at 09:38 on Tuesday.

DC

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE